Shingrix Vaccine Linked to Lower Dementia and Heart Disease Risk
New research suggests the shingles vaccine Shingrix may offer benefits well beyond preventing shingles, including reduced dementia onset and cardiovascular risk.
The shingles vaccine Shingrix has long been recommended for adults over 50 as a defense against the painful viral reactivation of chickenpox. But a growing body of scientific research is pointing toward something far more consequential: the possibility that Shingrix may help protect against dementia and heart disease, two of the most burdensome conditions in aging populations.
The emerging findings carry significant implications for public health, particularly as the population of Americans over 65 continues to expand. Dementia alone affects millions of older adults and currently has no cure, making any intervention that delays its onset — even modestly — a meaningful development worth examining carefully. Similarly, cardiovascular disease remains the leading cause of death in the United States, so an ancillary protective effect from a widely available vaccine would represent a notable public health dividend.
Read more BraveCity 230-LED Red Light Therapy Belt Drops to $95 →
The science here is still developing, and researchers are careful not to overstate causality. Observational studies can identify associations between vaccination and better health outcomes, but they cannot always rule out confounding factors — for instance, people who get vaccinated may already be more health-conscious in ways that independently reduce their disease risk. What makes the Shingrix findings compelling, though, is that the pattern appears consistent enough across multiple lines of research to warrant serious attention from clinicians and policymakers alike.
For now, the existing recommendations for Shingrix remain grounded in its proven efficacy against shingles itself, which can cause severe nerve pain and complications. The additional potential benefits — if confirmed through more rigorous trials — could eventually strengthen the case for higher vaccination rates among eligible adults who currently decline the shot. Uptake remains incomplete across the country, and a clearer picture of broader health benefits might shift that calculus for hesitant patients and their doctors.
Continue reading at MarketWatch.com
